Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Go back to Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics| (NASDAQ: GMAB) | Delayed: 32.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.96 | 52 Week High | $ | |||
| Open | $32.96 | 52 Week Low | $ | |||
| Day High | $32.96 | P/E | N/A | |||
| Day Low | $32.96 | EPS | $ | |||
| Volume | 7,545 | |||||

